Biotech startup Enveda raised $311 million in a Series E round to accelerate AI‑driven drug discovery from natural sources into human trials.
Enveda Biosciences announced a $311 million Series E financing round, aimed at scaling its AI‑powered platform that mines natural compounds for drug development.
Funding round details
The round was led by a consortium of venture firms, including Andreessen Horowitz and Sequoia Capital, with participation from existing investors such as General Catalyst and Lux Capital. The capital will be used to expand Enveda’s computational infrastructure, grow its scientific team, and move several pipeline candidates into Phase I clinical trials.
AI and nature‑derived drug discovery
Enveda’s platform combines deep learning models with high‑throughput screening of biodiversity‑derived molecules. By training algorithms on large datasets of natural product structures and bioactivity, the company claims it can predict therapeutic potential faster than traditional methods.
The startup says its approach has already identified promising leads for oncology, immunology, and metabolic disorders, with three candidates now ready for preclinical validation.
Strategic implications
Industry analysts view the sizable raise as a vote of confidence in AI‑driven discovery, especially as big pharma seeks to diversify pipelines beyond synthetic chemistry. Enveda’s focus on nature‑derived molecules could also address growing interest in sustainable drug sourcing.
- Accelerate AI model training with expanded cloud compute
- Scale up bioprospecting partnerships with academic institutions
- Advance three lead compounds into Phase I trials
We believe the convergence of AI and natural product chemistry will unlock a new generation of medicines, said Dr. Maya Patel, Enveda’s CEO.
The funding also positions Enveda to explore collaborations with pharmaceutical partners looking to integrate its platform into existing discovery workflows.
Comments
No comments yet.